Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InMIND: tafasitamab + rituximab + lenalidomide vs placebo + rituximab + lenalidomide in relapsed/refractory follicular lymphoma or marginal zone lymphoma
jRCT2021210065Phase 3Completed
- Sponsor
- Incyte
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) comparing tafasitamab + rituximab + lenalidomide with placebo + rituximab + lenalidomide (2 arms). Primary endpoints: Progression-free survival in follicular lymphoma population by investigator assessment using Lugano 2014 criteria and Kaplan-Meier estimates of progression-free survival in follicular lymphoma population by investigator assessment using Lugano 2014 criteria. Started Mar 2022; status: completed.
02
Drugs
tafasitamab
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on jRCT2021210065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210065.